Annals of Allergy, Asthma & Immunology

10/20/2026

Ready to submit an article? Share your expertise and submit it here:

Full-Function Web-Enabled Manuscript Submission and Tracking System for Peer Review

10/15/2026

Did you know Annals features collections of articles based on topic? Asthma, Clinical Practice, Mast Cells, Immunodeficiency, Rhinosinusitis, and more! Access them in the Collections area about halfway down the Annals homepage:

ACAAI Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

10/08/2026

Do you want to write an article for Annals? Here are our author guidelines:

ACAAI Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

10/06/2026

One institution’s experience with performing egg OIT assesses the safety and efficacy of 3 different office-based egg oral immunotherapy (OIT) protocols. Find out what they learned:

Egg allergy is one of the most common IgE-mediated food allergies. There is no treatment approved by the US Food and Drug Administration that allows the liberalization of egg into the diet. Studies have shown that oral immunotherapy (OIT) provides protection against accidental ingestion and may also...

10/01/2026

Comparing COVID-19-associated with AERD-associated chemosensory dysfunction (CSD), a study compares qualitative and quantitative chemosensory alterations and quality-of-life impact. Which differences between the groups were most striking?

Persistent chemosensory dysfunction (CSD) occurs in both COVID‑19 and aspirin-exacerbated respiratory disease (AERD). The similarities and differences in the chemosensory experiences of these 2 conditions remain undefined and poorly understood.

09/29/2026

Is adding dupilumab to medium-dose inhaled corticosteroids (ICS) superior to continuing high-dose ICS in patients with uncontrolled, moderate-to-severe asthma? Read more:

Escalating from medium-dose inhaled corticosteroid (ICS) to high-dose ICS in patients with asthma offers limited clinical benefit.

09/29/2026

Racial/ethnic disparities and worse socioeconomic conditions are associated with a reduced likelihood of FA resolution in children.

09/24/2026

This study assessed and evaluated the safety and efficacy of rapid drug desensitization for pediatric patients who had hypersensitivity reactions (HSRs) to chemotherapeutics, monoclonal antibodies, and disease-modifying antirheumatic drugs (DMARDs). Read more:

Drug hypersensitivity is often managed by drug desensitization, yet published data remain scarce in children. This study evaluated the safety and efficacy of rapid desensitization to chemotherapeutic agents, monoclonal antibodies, and disease-modifying antirheumatic drugs (DMARDs).

09/22/2026

Building on the Oxford Asthma Attack Risk Scale (ORACLE) studies, researchers examine the evidence supporting accessible type 2 (T2) inflammatory biomarkers—specifically blood eosinophils and fraction of exhaled nitric oxide (FeNO)—from initial diagnosis through treatment escalation. Learn more: https://www.annallergy.org/article/S1081-1206(26)00231-0/fulltext

09/17/2026

Distinguished Author Article: Precision medicine in atopic dermatitis strives to match defined phenotypes and molecular endotypes with the most appropriate therapy—from barrier-restoring topicals such as tapinarof to systemic JAKis and biologics targeting IL-4, IL-13, or OX40 pathways.